Associate Professor, Neurology, Emory University School of Medicine
Neurology
Dr. James J. Lah, MD
|
|
Give Review
James practices Neurology. He researched medicine at The Ohio State University College of Medicine. He over the years received 5 awards: "Outstanding Postdoc Mentor Award", "Tomorrows Leader in Alzheimers Disease Award", "Research Award for Clinical Trainees", "Medical Scientist Award" and "First Place, Landacre Research Forum". Dr. James J. Lah is also a published doctor. He has 64 publication published. The most recent publication is: CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease. James J. Lah is registered with Medicare and accepts Medicare payments.
Publications
- CSF beta-amyloid 1-42 - what are we measuring in Alzheimer's Disease?
- Rarity of the Alzheimer Disease-Protective APP A673T Variant in the United States.
- Aggregation Properties of the Small Nuclear Ribonucleoprotein U1-70K in Alzheimer Disease.
- Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease: A Genome-Wide Association Study.
- Quantitative phosphoproteomics of alzheimer's Disease reveals crosstalk between kinases and small heat shock proteins.
- Integrated Approaches for Analyzing U1-70K Cleavage in Alzheimer's Disease.
- Aggregates of small nuclear ribonucleic acids (snRNAs) in Alzheimer's Disease.
- Biomarkers for Predicting Cognitive Decline in those with Normal Cognition.
- AAV2 production with optimized N/P ratio and PEI-mediated transfection results in low toxicity and high titer for in vitro and in vivo applications.
- U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's Disease.
- Neuron enriched nuclear proteome isolated from human Brain.
- Proteomic analysis of postsynaptic density in Alzheimer's Disease.
- NF-κB activity is inversely correlated to RNF11 expression in Parkinson's Disease.
- Behavior matters-cognitive predictors of survival in amyotrophic lateral sclerosis.
- A behavioral task predicts conversion to mild cognitive impairment and Alzheimer's Disease.
- RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-?B signaling in dopaminergic cells.
- Hippocampal ProNGF Signaling Pathways and β-Amyloid Levels in Mild Cognitive Impairment and Alzheimer Disease.
- Neuronal LR11 Expression Does Not Differentiate between Clinically-Defined Alzheimer's Disease and Control Brains.
- Coaggregation of RNA-Binding Proteins in a Model of TDP-43 Proteinopathy with Selective RGG Motif Methylation and a Role for RRM1 Ubiquitination.
- Comparative distribution of protein components of the A20 ubiquitin-editing complex in normal human Brain.
- Analysis of a membrane-enriched proteome from postmortem human brain tissue in Alzheimer's Disease.
- Neurocognitive correlates of nocturnal oxygen desaturation in a memory clinic population.
- Aberrant Septin 11 is Associated with Sporadic Frontotemporal Lobar Degeneration.
- An exploration of subgroups of mild cognitive impairment based on cognitive, neuropsychiatric and functional features: analysis of data from the national Alzheimer's ...
- Exogenous seeding of Cerebral ?-amyloid deposition in ?APP-transgenic rats.
- Autosomal Recessive Causes Likely in Early-Onset Alzheimer Disease.
- Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's Disease.
- Polyubiquitin linkage profiles in three models of proteolytic stress suggest the etiology of Alzheimer Disease.
- Rho kinase II phosphorylation of the lipoprotein receptor LR11/SORLA alters amyloid-beta production.
- Phosphoproteomic analysis reveals site-specific changes in GFAP and NDRG2 phosphorylation in frontotemporal lobar degeneration.
- Paraoxonase-1 polymorphisms in Alzheimer's Disease, Parkinson's Disease, and AD-PD spectrum Diseases.
- Differential effects of allosteric M(1) muscarinic acetylcholine receptor agonists on receptor activation, arrestin 3 recruitment, and receptor downregulation.
- Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers.
- Multiplex SILAC analysis of a cellular TDP-43 proteinopathy model reveals protein inclusions associated with SUMOylation and diverse polyubiquitin chains.
- DHA diet reduces AD pathology in young APPswe/PS1 Delta E9 transgenic mice: possible gender effects.
- Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo.
- Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions.
- A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in rev...
- Proteomics analysis reveals novel components in the detergent-insoluble subproteome in Alzheimer's Disease.
- Is ApoE epsilon4 associated with cognitive functioning in African Americans diagnosed with Alzheimer Disease? An exploratory study.
- Eye tracking during a visual paired comparison task as a predictor of early Dementia.
- White Matter Integrity and Episodic Memory Performance in Mild Cognitive Impairment: A Diffusion Tensor Imaging Study.
- Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's Disease.
- Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats.
- Effects of hypertension and hypercholesterolemia on cognitive functioning in patients with alzheimer Disease.
- Fas-associated factor 1 and Parkinson's Disease.
- Phosphoproteomic analysis of human Brain by calcium phosphate precipitation and mass spectrometry.
- Proteomic identification of novel proteins associated with Lewy bodies.
- Mint3/X11gamma is an ADP-ribosylation factor-dependent adaptor that regulates the traffic of the Alzheimer's Precursor protein from the trans-Golgi network.
- Neuronal LR11/sorLA expression is reduced in mild cognitive impairment.
- Evidence of shared risk for Alzheimer's Disease and Parkinson's Disease using family history.
- PARK10 candidate RNF11 is expressed by vulnerable neurons and localizes to Lewy bodies in Parkinson Disease brain.
- Daytime sleepiness and functional impairment in Alzheimer Disease.
- LR11/SorLA expression is reduced in sporadic Alzheimer Disease but not in familial Alzheimer Disease.
- The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments.
- Merger of laser capture microdissection and mass spectrometry: a window into the amyloid plaque proteome.
- Feasibility of ambulatory overnight oximetry in consecutive patients in a Dementia clinic.
- Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection.
- Loss of apolipoprotein E receptor LR11 in Alzheimer Disease.
- Munc18 interacting proteins: ADP-ribosylation factor-dependent coat proteins that regulate the traffic of beta-Alzheimer's precursor protein.
- Endoproteolysis of beta-secretase (beta-site amyloid precursor protein-cleaving enzyme) within its catalytic domain. A potential mechanism for regulation.
- Rab11a and myosin Vb regulate recycling of the M4 muscarinic acetylcholine receptor.
- CSF complement 3 and factor H are staging biomarkers in Alzheimer's Disease.
Schools
Ohio State University College of Medicine
Emory University School Of Med
Procedures Preformed
- EEG (Electroencephalogram)
Conditions Treated
- Alzheimer's Disease
- Ataxia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Cerebral Artery Thrombosis
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- Outstanding Postdoc Mentor Award
- Tomorrow’s Leader in Alzheimer’s Disease Award
- Research Award for Clinical Trainees
- Medical Scientist Award
- First Place, Landacre Research Forum
Education
-
Emory University -
Ohio State University -
The Ohio State University College of Medicine -
Duke University
Hospital
-
Emory University Hospital
Drug Facts
| NPI NUMBER | 1952358582 | |
| NPPES Provider LastName | LAH | |
| NPPES Provider FirstName | JAMES | |
| NPPES Provider ZIPCode | 303294021 | |
| NPPES Provider State | GA | |
| Specialty Description | Neurology | |
| Total Claim Count | 1364.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1952358582 |
| Last Name Of The Provider | LAH |
| First Name Of The Provider | JAMES |
| View All |
Similar Doctors
|
|
Dr. Nicolas S. Krawiecki, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Angela Ashley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William Elsner, MD |
|
|
Dr. Donald S. Orr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John A. Fraser, MD |
|
|
Dr. Beth A. Leeman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew T. Guidry, MD |
|
|
Dr. Amy R. Harrison, MD |
|
|
Thomas G. Burns |